Clinical Commander

Back to dossier
neuro.brain-abscess.v1PRODUCTION
neuro.brain-abscess.v1

Brain Abscess (Pyogenic)

neurologyacuteadultgeriatric
Hard-required inputs
0 / 15
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Pyogenic CNS focal infection — neurosurgical + ID + neurology multi-D management; ESCMID 2024 (Bodilsen PMID 37648062) is canonical

Inputs
1
Actions
0
Advance rule
Set
Advance when

Brain abscess on differential

Patient inputs (21)

Adults median age 58 (Bodilsen CID 2024 PMID 37946527); incidence rising in elderly (Omland/Bodilsen 2024 PMID 38547383)

GCS quantifies AMS severity; GCS ≤8 = intubation; serial monitoring drives ICP / herniation triggers (ESCMID 2024 PMID 37648062)

Cushing reflex (HTN + bradycardia) marker of impending herniation; baseline + serial

HIV / transplant / chemo / hematologic malignancy — expands differential to Nocardia + fungal + Toxo + mycobacterial; broadens empiric coverage to TMP-SMX + voriconazole (ESCMID 2024 PMID 37648062)

Post-neurosurgical / post-traumatic source → S. aureus + GNR incl Pseudomonas → empiric meropenem + vancomycin or linezolid (ESCMID 2024 PMID 37648062)

Endocarditis / IVDU / valvular disease → hematogenous source → empiric vancomycin coverage + TTE/TEE workup

Otogenic / odontogenic / sinogenic / hematogenous / post-traumatic / post-neurosurgical / immunocompromised / cryptogenic — drives empiric coverage selection (ESCMID 2024 PMID 37648062)

Headache in ~70% — most common single symptom (Bodilsen CID 2024 PMID 37946527)

Fever present in only ~50% (Bodilsen CID 2024 PMID 37946527) — afebrile presentation common; cannot exclude on absence

Vancomycin / aminoglycoside / amphotericin nephrotoxicity; baseline Cr + CrCl drives dose

Leukocytosis variable (only ~60-70%); baseline before therapy

CRP + ESR elevated in ~80%; supports inflammatory milieu; serial for treatment response (CRP weekly)

Positive in ~25-30% (higher with hematogenous / endocarditis source); MUST draw before empiric abx

MRI gold-standard — ring-enhancing lesion + central DWI restriction differentiates abscess from neoplasm; ESCMID 2024 PMID 37648062 strong/high recommendation

Focal deficit in ~40-86% by series (Bodilsen CID 2024 PMID 37946527: 86% any deficit); drives MRI urgency + neurosurgery consult

PAVM (HHT) and right-to-left shunt — risk factor for cryptogenic abscess; bubble-echo + chest CT (Bodilsen 2024 PMID 38064178)

Stereotactic aspirate is the diagnostic gold-standard — gram + culture + 16S PCR / molecular if available; ESCMID 2024 PMID 37648062 recommends molecular diagnostics when cultures negative

Sinus / temporal-bone CT (sinogenic / otogenic); panoramic / dental CT (odontogenic); TTE → TEE (endocarditis); CT chest (PAVM / pulmonary source); CT body if cryptogenic adult

Seizure in ~25%; post-abscess epilepsy ~30% long-term — drives AED selection + outpatient surveillance

HIV status drives differential (toxoplasmosis prior; HAART status) and empiric coverage breadth

CT acceptable if MRI delay; ring-enhancing lesion with surrounding edema; sensitivity lower than MRI

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (16)

16 need judgement
  • informationallife_threateninggcs_<=8_brain_abscess
    GCS ≤8 at presentation or decline (ESCMID 2024 PMID 37648062)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningintraventricular_rupture
    Abscess rupture into ventricular system on imaging (Bodilsen/Eriksen CID 2026 PMID 40476360)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmidline_shift_>5mm
    Midline shift >5 mm or impending uncal / transtentorial herniation (ESCMID 2024 PMID 37648062)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstatus_epilepticus_brain_abscess
    Status epilepticus (clinical or electrographic) (ESCMID 2024 PMID 37648062)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningphenotype_hematogenous_endocarditis
    Known / suspected infective endocarditis / IVDU / valvular disease; multiple abscesses; S. aureus + viridans Strep
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningphenotype_immunocompromised
    HIV CD4 <200 / transplant / chemotherapy / chronic high-dose steroid; broad pathogen spectrum including Nocardia + Aspergillus + Mucor + Toxoplasma + TB
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereabscess_>=2.5cm_accessible
    Abscess ≥2.5 cm diameter and accessible to neurosurgery (Bodilsen/Eriksen CID 2026 PMID 40476360; UK survey PMID 42081068)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremulti_loculated_or_posterior_fossa
    Multi-loculated abscess OR posterior fossa location with brainstem compression / hydrocephalus
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereseptic_shock_overlap
    Septic physiology (qSOFA ≥2 / lactate ≥2 / hypotension MAP <65)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_immunocompromise
    HIV CD4 <200 / solid-organ or stem-cell transplant / chronic high-dose corticosteroid / chemotherapy with neutropenia (ESCMID 2024 PMID 37648062)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_otogenic
    Otitis media / mastoiditis / cholesteatoma source; temporal lobe or cerebellar abscess; Streptococcus (anginosus group) + anaerobes
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_odontogenic
    Recent dental procedure / dental abscess / poor oral hygiene; frontal lobe abscess; Streptococcus + Fusobacterium + Actinomyces
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_sinogenic
    Sinusitis (especially frontal / sphenoid) source; frontal lobe abscess; Streptococcus + anaerobes
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_post_traumatic
    Penetrating head trauma / open skull fracture / foreign body; S. aureus + GNR
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_post_neurosurgical
    Recent craniotomy / VP shunt / EVD / deep brain stimulation; S. aureus (incl MRSA) + coag-neg staph + GNR incl Pseudomonas
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverephenotype_cryptogenic
    No identifiable source after standard workup (~30% per Bodilsen CID 2024 PMID 37946527); consider PAVM / R-L shunt (Bodilsen 2024 PMID 38064178)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives severity classification
Loading…

Recommended regimen

Brain-abscess empiric + targeted regimen — ESCMID 2024 (Bodilsen Clin Microbiol Infect PMID 37648062) ladder by host + source
axis: brain_abscess_empiric_targeted_treatmentstep 1 - Step 1 — Community-acquired, immunocompetent (ESCMID 2024 PMID 37648062 strong/moderate)
Selected step "Step 1 — Community-acquired, immunocompetent (ESCMID 2024 PMID 37648062 strong/moderate)" — Community-acquired brain abscess; no recent neurosurgery / trauma; no severe immunocompromise
  • ceftriaxone
    first line
    3rd_gen_cephalosporin
    2 g IV q12h • IV • q12h (max: 4 g/day)
    triggers: community_acquired_immunocompetent
    ESCMID 2024 PMID 37648062 strong/moderate — 3rd-gen cephalosporin covers Streptococcus anginosus group + Streptococcus + most Enterobacterales; high CNS penetration; q12h for CNS dosing (vs q24h for routine bacteremia)
    rxcui 2193
  • metronidazole
    first line
    nitroimidazole
    500 mg IV q8h (or 15 mg/kg IV load then 7.5 mg/kg q6h) • IV • q8h
    triggers: community_acquired_immunocompetent, anaerobic_coverage_required
    ESCMID 2024 PMID 37648062 strong/moderate — covers Bacteroides + Fusobacterium + Prevotella; essential for odontogenic + otogenic + sinogenic sources (Bodilsen CID 2024 PMID 37946527 oral-cavity polymicrobial 41%); excellent CNS penetration
    rxcui 6922

ed playbook — drug actions (8)

  1. 1. ceftriaxone
    rxcui 2193
    2 g IV q12h • IV • q12h
    trigger: EMPIRIC community-acquired immunocompetent — start after blood cultures × 2
    ESCMID 2024 PMID 37648062 strong/moderate
  2. 2. metronidazole
    rxcui 6922
    500 mg IV q8h • IV • q8h
    trigger: Concurrent with ceftriaxone — anaerobe coverage
    ESCMID 2024 PMID 37648062 strong/moderate
  3. 3. vancomycin
    rxcui 11124
    15-20 mg/kg IV q8-12h (target trough 15-20) • IV • q8-12h
    trigger: MRSA risk: IVDU / hardware / dialysis / post-neurosurgical / hematogenous endocarditis
    ESCMID 2024 PMID 37648062 — covers MRSA + viridans Strep
  4. 4. meropenem (substitute ceftriaxone)
    rxcui 29561
    2 g IV q8h (CNS dose) • IV • q8h
    trigger: Post-neurosurgical / post-traumatic — broaden to cover Pseudomonas + GNR
    ESCMID 2024 PMID 37648062 conditional/low post-neurosurgical regimen
  5. 5. TMP-SMX + voriconazole
    rxcui 10831
    TMP-SMX 5 mg/kg TMP IV q6-8h + voriconazole 6 mg/kg IV q12h × 2 then 4 mg/kg q12h • IV • per drug
    trigger: Severe immunocompromise (HIV / transplant / chemo)
    ESCMID 2024 PMID 37648062 conditional/low — Nocardia + fungal coverage
  6. 6. dexamethasone (selective)
    rxcui 3264
    10 mg IV q6h (0.15 mg/kg) • IV • q6h
    trigger: Severe perilesional oedema with midline shift / impending herniation ONLY
    ESCMID 2024 PMID 37648062 strong/low — NOT routine; selective use
  7. 7. levetiracetam
    rxcui 114477
    1 g IV load over 15 min then 500-1000 mg q12h • IV • q12h
    trigger: Clinical seizure OR electrographic seizure
    No routine prophylaxis per ESCMID 2024 PMID 37648062
  8. 8. acetaminophen
    1 g PO/IV q6h PRN fever • PO/IV • q6h PRN
    trigger: Fever
    Antipyretic adjunct; aggressive fever control reduces metabolic demand

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: New persistent headache + focal deficit (~40% — Bodilsen CID 2024 PMID 37946527; classic triad only ~22% complete); Fever + focal neurological deficit / new seizure / AMS — pivot to brain-abscess workup (ESCMID 2024 PMID 37648062); New seizure in patient with otitis / sinusitis / dental / endocarditis / immunocompromise / post-neurosurgical context.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Brain Abscess (Pyogenic)** (neuro.brain-abscess.v1).
Phenotype framing: By source: otogenic (Strep + anaerobes; temporal lobe / cerebellum) / odontogenic (Strep + Fusobacterium + Actinomyces; frontal) / sinogenic (Strep; frontal) / hematogenous (S. aureus + viridans Strep) / post-traumatic (S. aureus + GNR) / post-neurosurgical (S. aureus + GNR incl Pseudomonas) / immunocompromised (Toxo + Nocardia + fungal + TB) / cryptogenic (~30%; oral-cavity polymicrobial dominant — Bodilsen CID 2024 PMID 37946527). Non-infectious mimics on imaging: glioma / metastasis / lymphoma (DWI helps); toxoplasmosis (HIV); tuberculoma; cysticercosis
Scope: Pyogenic CNS focal infection — neurosurgical + ID + neurology multi-D management; ESCMID 2024 (Bodilsen PMID 37648062) is canonical

No severity triggers fired against current inputs.

Plan

Regimen axis: **Brain-abscess empiric + targeted regimen — ESCMID 2024 (Bodilsen Clin Microbiol Infect PMID 37648062) ladder by host + source** — step "Step 1 — Community-acquired, immunocompetent (ESCMID 2024 PMID 37648062 strong/moderate)".
1. ceftriaxone 2 g IV q12h IV q12h (3rd_gen_cephalosporin, first line) — ESCMID 2024 PMID 37648062 strong/moderate — 3rd-gen cephalosporin covers Streptococcus anginosus group + Streptococcus + most Enterobacterales; high CNS penetration; q12h for CNS dosing (vs q24h for routine bacteremia)
2. metronidazole 500 mg IV q8h (or 15 mg/kg IV load then 7.5 mg/kg q6h) IV q8h (nitroimidazole, first line) — ESCMID 2024 PMID 37648062 strong/moderate — covers Bacteroides + Fusobacterium + Prevotella; essential for odontogenic + otogenic + sinogenic sources (Bodilsen CID 2024 PMID 37946527 oral-cavity polymicrobial 41%); excellent CNS penetration

Setting playbook (ed) — Recognise brain-abscess pattern (headache + focal deficit / new seizure / AMS in predisposing context); STAT contrast MRI brain + blood cultures × 2 + multi-D activation (ID + neurology + neurosurgery); empiric IV abx IMMEDIATELY after cultures if neurosurgery >24 h or critically ill (ESCMID 2024 PMID 37648062)
3. ceftriaxone 2 g IV q12h IV q12h — EMPIRIC community-acquired immunocompetent — start after blood cultures × 2 (ESCMID 2024 PMID 37648062 strong/moderate)
4. metronidazole 500 mg IV q8h IV q8h — Concurrent with ceftriaxone — anaerobe coverage (ESCMID 2024 PMID 37648062 strong/moderate)
5. vancomycin 15-20 mg/kg IV q8-12h (target trough 15-20) IV q8-12h — MRSA risk: IVDU / hardware / dialysis / post-neurosurgical / hematogenous endocarditis (ESCMID 2024 PMID 37648062 — covers MRSA + viridans Strep)
6. meropenem (substitute ceftriaxone) 2 g IV q8h (CNS dose) IV q8h — Post-neurosurgical / post-traumatic — broaden to cover Pseudomonas + GNR (ESCMID 2024 PMID 37648062 conditional/low post-neurosurgical regimen)
7. TMP-SMX + voriconazole TMP-SMX 5 mg/kg TMP IV q6-8h + voriconazole 6 mg/kg IV q12h × 2 then 4 mg/kg q12h IV per drug — Severe immunocompromise (HIV / transplant / chemo) (ESCMID 2024 PMID 37648062 conditional/low — Nocardia + fungal coverage)
8. dexamethasone (selective) 10 mg IV q6h (0.15 mg/kg) IV q6h — Severe perilesional oedema with midline shift / impending herniation ONLY (ESCMID 2024 PMID 37648062 strong/low — NOT routine; selective use)
9. levetiracetam 1 g IV load over 15 min then 500-1000 mg q12h IV q12h — Clinical seizure OR electrographic seizure (No routine prophylaxis per ESCMID 2024 PMID 37648062)
10. acetaminophen 1 g PO/IV q6h PRN fever PO/IV q6h PRN — Fever (Antipyretic adjunct; aggressive fever control reduces metabolic demand)

Non-pharmacologic actions:
- Activate brain-abscess pathway + ID + neurology + neurosurgery consults (ESCMID 2024 PMID 37648062)
- Two large-bore IVs + continuous SpO2 + cardiac monitor + telemetry
- NPO + aspiration precautions if dysphagia or GCS decline
- HOB 30° if raised ICP suspected
- Avoid LP pre-imaging — herniation risk in mass-effect lesion
- STAT MRI brain transport with airway protection capability if GCS borderline
- Document time-of-decision-to-abx + time-given + time-of-neurosurgery-consult

AVOID / contraindication checks:
- LP_contraindicated_in_brain_abscess_pre_imaging (mass effect / herniation risk; MRI first)
- Do_NOT_delay_abx_for_aspiration_if_neurosurgery_>24h (ESCMID 2024 PMID 37648062 conditional/low; abx may be withheld until aspiration only if neurosurgery within reasonable time)
- Vancomycin_trough_15 20_for_CNS_dosing (higher than soft tissue trough 10 15)
- Meropenem_2g_q8h_CNS_dosing (higher than routine 1 g q8h)
- No_routine_corticosteroid (ESCMID 2024 PMID 37648062 — dexamethasone only for severe mass effect / impending herniation)
- No_routine_AED_prophylaxis (ESCMID 2024 PMID 37648062 conditional/very low — AED only for clinical / electrographic seizure)
- Voriconazole_TDM_trough_day_5_target_1 5.5_mg_per_L (efficacy + toxicity driven; QTc + LFT monitoring)
- Liposomal_amphotericin_for_mucor_not_voriconazole (voriconazole inactive against Mucorales)
- Neurosurgery_halves_mortality_and_rupture_vs_nonoperative (Bodilsen/Eriksen CID 2026 PMID 40476360 — adjusted RR 2.47 for mortality with nonoperative)
- Source_control_required (ENT for otogenic/sinogenic; dental for odontogenic; cardiac surgery for endocarditis; embolization for PAVM)

Monitoring

Regimen monitoring:
- Daily neuro exam + GCS (ESCMID 2024 PMID 37648062)
- CBC + CRP + ESR weekly (CRP trajectory drives duration response)
- BMP + LFT weekly (vanc / TMP-SMX nephrotoxicity; voriconazole / amph hepatotoxicity)
- Vancomycin trough q-dose initially target 15-20 mg/L
- Voriconazole trough day 5 target 1-5.5 mg/L
- Repeat MRI brain at 2 wk → 4-6 wk → end-of-therapy (UK survey PMID 42081068)
- cEEG if persistent AMS / refractory seizure / NCSE suspicion
- Aspirate / surgical specimen — gram + culture + 16S rRNA PCR / molecular when cultures negative (ESCMID 2024 PMID 37648062)
- Source-control follow-up imaging — sinus / dental / cardiac echo / chest CT for PAVM

Setting (ed) monitoring:
- Neuro exam q1-2 h (GCS) (ESCMID 2024 PMID 37648062)
- Continuous SpO2 + cardiac monitor
- Cr + UO q-shift
- Glucose q6h
- BP target SBP 100-160 (avoid hypotension to preserve CPP; avoid HTN spike in mass-effect)

Follow-up plan: OPAT for IV completion if clinically stable + reliable access + ID-OPAT capacity; neurology clinic at 6-8 wk + 6 mo + 12 mo (AED management, neurocognitive battery, return-precautions for late epilepsy ~30%); ID clinic at end-of-therapy; source-control follow-up (dental, ENT, cardiology, pulmonology for PAVM — bubble-echo + chest CT per Bodilsen 2024 PMID 38064178); driving evaluation per jurisdictional regulation
- Close-out criterion: Long-term plan documented + OPAT / rehab arranged

Monitoring phase: Daily neuro exam + GCS; CBC + CRP + ESR weekly (CRP-trajectory drives duration); BMP + LFT weekly; vancomycin trough q-dose initially; voriconazole trough day 5; repeat MRI at 2 wk → 4-6 wk → end-of-therapy (UK survey PMID 42081068 shows variable cadence; ESCMID 2024 PMID 37648062 conditional/very low for routine reimaging); cEEG if persistent AMS or refractory seizure

Disposition

Current setting: ed — Recognise brain-abscess pattern (headache + focal deficit / new seizure / AMS in predisposing context); STAT contrast MRI brain + blood cultures × 2 + multi-D activation (ID + neurology + neurosurgery); empiric IV abx IMMEDIATELY after cultures if neurosurgery >24 h or critically ill (ESCMID 2024 PMID 37648062)

Disposition criteria:
- Admit ICU if intubated / status / impending herniation / multi-loculated / haemodynamic instability
- Admit neurology / ID / neurosurgery floor for routine 6-8 wk IV course
- Transfer to neurosurgery-capable tertiary centre if local lacks neurosurgery
- NEVER discharge from ED — outpatient course is OPAT continuation only

Escalation triggers (move to higher acuity):
- GCS ≤ 8 → intubate + ICU
- Status epilepticus → midazolam load + infusion + ICU (route to neuro.status-epilepticus.core.v1)
- Cushing reflex / herniation signs → mannitol or hypertonic saline + STAT neurosurgery + ICU
- Multi-loculated or rupture into ventricle → STAT neurosurgery + ICU
- Septic physiology / lactate ≥ 4 → SSC 2026 hour-1 bundle + ICU

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] GCS ≤8 at presentation or decline (ESCMID 2024 PMID 37648062)
- [LIFE_THREATENING] Abscess rupture into ventricular system on imaging (Bodilsen/Eriksen CID 2026 PMID 40476360)
- [LIFE_THREATENING] Midline shift >5 mm or impending uncal / transtentorial herniation (ESCMID 2024 PMID 37648062)

Citations

- ESCMID 2024 guideline on diagnosis and treatment of brain abscess in children and adults (Bodilsen Clin Microbiol Infect 2024;30(1):66-89) [PMID:37648062](https://pubmed.ncbi.nlm.nih.gov/37648062/)
- Cited evidence (PMID 38309325) [PMID:38309325](https://pubmed.ncbi.nlm.nih.gov/38309325/)
- Cited evidence (PMID 25075836) [PMID:25075836](https://pubmed.ncbi.nlm.nih.gov/25075836/)
- Cited evidence (PMID 37946527) [PMID:37946527](https://pubmed.ncbi.nlm.nih.gov/37946527/)
- Cited evidence (PMID 40476360) [PMID:40476360](https://pubmed.ncbi.nlm.nih.gov/40476360/)

Last reconciled with current guidelines: 2026-05-26.
References
  • ESCMID 2024 guideline on diagnosis and treatment of brain abscess in children and adults (Bodilsen Clin Microbiol Infect 2024;30(1):66-89) — PMID:37648062
  • Cited evidence (PMID 38309325) — PMID:38309325
  • Cited evidence (PMID 25075836) — PMID:25075836
  • Cited evidence (PMID 37946527) — PMID:37946527
  • Cited evidence (PMID 40476360) — PMID:40476360